Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes. Issue 3 (25th March 2022)

• Record Type: Journal Article
• Authors: Rozema, Johanne; Hoogendoorn, Mels; Potma, Iris; ten Seldam, Inge; Veeger, Nic J. G. M.; Kibbelaar, Robby E.; van de Loosdrecht, Arjan A.; van Roon, Eric N.
• Is Part Of: EJHaem. Volume 3:Issue 3(2022)
• Page Start: 775
• Page End: 784
• Publication Date: 2022-03-25
• Subjects: anti‐infective agent -- infections -- myelodysplastic syndromes -- population‐based; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.422
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This study examines prescription rates of anti‐infective agents in MDS patients before and after diagnosis, in both in‐ and outpatient settings, to provide information on infection management in clinical practice. We performed a population‐based study using the HemoBase registry, containing data of all MDS patients diagnosed since 2005 in Friesland, the Netherlands. Community and hospital pharmacies provided prescription data from 1995 to 2020. Data were obtained for 203 of 292 patients (70%). Patients received significantly more anti‐infective agents, predominantly antibacterials (70%), after diagnosis compared to before: 148.7 defined daily dose/1000 days (DID) (95% CI: 146.9–150.5) and 55.1 DID (95% CI: 54.5–55.8, p < 0.01), respectively, corresponding to median 23.5 and 7.6 treatment days/year. Higher‐risk (449.9 DID) and lower‐risk patients (129.1 DID) both received significantly more anti‐infective agents after diagnosis; comorbidities, neutropenia, and age did not show significant differences relative to prescription rates. Before diagnosis, 10% of patients had infection‐related hospital admissions versus 38% after diagnosis. In conclusion, MDS patients received significantly more anti‐infective agents compared to before diagnosis. This is the first study that has quantified the prescription rate of anti‐infective agents within and beyond the clinical setting in MDS.